Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Non Operating Income (2022 - 2025)

Lexaria Bioscience's Non Operating Income history spans 4 years, with the latest figure at -$22081.0 for Q4 2025.

  • For Q4 2025, Non Operating Income fell 38.69% year-over-year to -$22081.0; the TTM value through Nov 2025 reached -$36857.0, down 44.26%, while the annual FY2025 figure was -$30697.0, 44.71% up from the prior year.
  • Non Operating Income for Q4 2025 was -$22081.0 at Lexaria Bioscience, down from -$8631.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $34040.0 in Q1 2025 and bottomed at -$134902.0 in Q3 2023.
  • The 4-year median for Non Operating Income is -$15921.0 (2024), against an average of -$22061.9.
  • The largest annual shift saw Non Operating Income tumbled 339.28% in 2024 before it surged 122.89% in 2025.
  • A 4-year view of Non Operating Income shows it stood at -$73887.0 in 2022, then skyrocketed by 37.88% to -$45896.0 in 2023, then skyrocketed by 65.31% to -$15921.0 in 2024, then plummeted by 38.69% to -$22081.0 in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Non Operating Income are -$22081.0 (Q4 2025), -$8631.0 (Q3 2025), and -$40185.0 (Q2 2025).